Prof Bradley Monk talks to ecancer for the ESMO 2021 meeting about the results from the phase III KEYNOTE-826 study which looked at the addition of pembrolizumab to chemotherapy for recurrent, persistent or metastatic cervical cancer.
He explains that this was a randomised, double-blind study of 617 patients where the addition of pembrolizumab was compared to placebo on top of carboplatin/cisplatin and paclitaxel.
Prof Monk reports that the study met primary endpoints of overall survival and progression free survival with a 33% improvement in patients that were alive at 2 years in the all-comers subgroup.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.